Dias Malik

Dias Malik

Auto-generated profile, based on publicly available information

Dias Malik

“University Medical Center” Corporate Fund, Astana, Kazakhstan

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 April 2025 in Scientific Reports
Verified
Journal Article
Open access
PDF file
MBMirgul Bayanova
Mirgul Bayanova
AAAigerim Abilova
Aigerim Abilova
MRMarzhan Rakhimzhanova
Marzhan Rakhimzhanova
ABAssiya Bazenova
Assiya Bazenova
LNLyazzat Nazarova
Lyazzat Nazarova
ABAidos Bolatov
Aidos Bolatov
This study investigates the genetic landscape and phenotypic spectrum of osteogenesis imperfecta (OI) in the Kazakhstani pediatric population, focusing on 40 children diagnosed and treated at the “University Medical Center” Corporate Fund from July 2021 to June 2023. Genetic analysis was conducted using whole-genome sequencing for 22 participants at the “National Laboratory Astana” (Nazarbayev University, Astana, Kazakhstan) and whole-exome sequencing for 18 participants in private laboratories. Clinically significant genetic variants were found in 35 cases (87.5%). Mutations in the COL1A1 and COL1A2 genes were detected in 24 cases (68.6%), among them 5 variants were described for the first time. Among the rare cases of OI, variants in the IFITM5 (n = 2), SERPINF1 (n = 7), and SERPINH1 (n = 1) genes were identified. At the same time, seven unrelated cases had identical variants in the SERPINF1 gene (c.907C > T, 6 of which in the homozygous and 1 in the compound heterozygous state) and two cases in the IFITM1 gene (c.-14C > T). Novel disease-causing variants were identified in 17% of cases, and a higher proportion of collagen defects were seen. The relatively high proportion of autosomal recessive inherited OI determined in the current study should be investigated at the population level in Kazakhstan and in the countries of Central Asia. Moreover, this study described the genotype–phenotype correlation, which complements and expands the existing knowledge about the OI.

25 April 2024 in Journal of Clinical Medicine of Kazakhstan
Verified
Journal Article
Open access
PDF file
MBMirgul Bayanova
Mirgul Bayanova
AZAida Zhenissova
Aida Zhenissova
LNLyazzat Nazarova
Lyazzat Nazarova
AAAizhan Abdikadirova
Aizhan Abdikadirova
MSMalika Sapargalieyva
Malika Sapargalieyva
YPYuriy Pya
Yuriy Pya
Kidney transplantation stands as the ultimate recourse for restoring vital organ functions, particularly in cases of end-stage kidney disease where alternative treatments, such as dialysis, prove less effective. With over 102,000 kidney transplants conducted globally in 2022, the demand for organ transplantation is ever-increasing, fueled by a rising incidence of end-stage renal disease attributed to causes like diabetes and hypertension. Despite significant advancements in kidney transplantation, immunosuppressive therapy remains crucial to preventing graft rejection. Tacrolimus (TAC), a calcineurin inhibitor, plays a pivotal role in this regard. Discovered in 1984, TAC inhibits T-lymphocyte activation, preventing acute rejection by disrupting the transcription of crucial genes involved in early T-cell activation. However, the use of TAC is not without challenges. The drug exhibits serious side effects, a narrow therapeutic index, and unpredictable pharmacokinetics. Therapeutic drug monitoring (TDM) becomes imperative in daily practice to maintain TAC blood concentrations within the therapeutic range. This literature review delves into the genetic aspects influencing TAC metabolism, focusing on key polymorphisms in CYP3A5, CYP3A4, and ABCB1 genes. Genetic variations in CYP3A5, a major enzyme in TAC metabolism, impact enzyme activity, necessitating personalized dosing strategies. CYP3A4 polymorphisms, especially CYP3A4*22, demonstrate associations with altered TAC clearance and dose requirements. The ABCB1 gene, encoding P-glycoprotein, another player in TAC pharmacokinetics, also exhibits polymorphisms influencing drug absorption and distribution. The ABCB1 3435C>T variant, in particular, shows potential implications on Tacrolimus bioavailability. Understanding these genetic variations aids in the development of personalized dosing regimens. Studies suggest that tailoring TAC doses based on CYP3A5 genotypes significantly improves the proportion of patients achieving therapeutic concentrations. Additionally, incorporating genetic information, particularly CYP3A4*22, into dosing strategies enhances the precision of TAC therapy, reducing the risk of adverse effects.

14 November 2024 in Наука и здравоохранение
Verified
Journal Article
Open access
MBMirgul Bayanova
Mirgul Bayanova
AAAskerbekova A.
Askerbekova A.
NLNazarova L.
Nazarova L.
AAAbdikadirova A.
Abdikadirova A.
SMSapargaliyeva M.
Sapargaliyeva M.
ABAidos Bolatov
Aidos Bolatov
Heart transplantation (HT) is the standard of care for end-stage heart failure refractory to medical therapy. Patients after heart transplantation are at risk of developing various complications during their follow-up. Common complications include early allograft failure, acute graft rejection (AGR), coronary allograft vasculopathy (CAV), renal failure, infections, and cancer. Causes for secondary graft dysfunction need to be considered beyond the first week. Nowadays, histological stratification of acute rejection (AR) on endomyocardial biopsy plus histopathology (EMBx) is the standard method for diagnosing acute rejection, assessing its severity, and the response to therapy. Unfortunately, this method is invasive and has some limitations. In addition to that, acute rejection has two phenotypes, acute cellular rejection (ACR) and antibody-mediated rejection (AMR), which challenges the histopathologic diagnosis. Secondary non-genetic methods for monitoring cardiac rejection may include echocardiography, cardiac MRI, troponin, and other methods. A reliable non-invasive marker to detect acute rejection prior to the development of graft dysfunction would possibly result in better outcomes for those patients who develop allograft rejection. In the current review, we collect recent data about genetic non-invasive biomarkers including donor derived cell free DNA, DNA-methylation, RNAs Gene expression profiling (messenger RNA) and micro-RNA. cfDNA methylation analysis can help to distinguish different types of acute rejection. The fraction of cfDNA from the donor decreases rapidly post-transplantation, and increase only in case of acute rejection or myocardial injury. In summary, genetic non-invasive methods have a pivotal role in the assessing and monitoring cardiac allograft rejection. Review article established that DNA-based non-invasive tools minimize the risks of invasive procedures. It is a safe, convenient, and precise method for diagnosing heart failure after cardiac transplantation. Трансплантация сердца является стандартом лечения терминальной сердечной недостаточности, резистентной к медикаментозной терапии. Пациенты после трансплантации сердца подвергаются риску развития различных осложнений во время наблюдения. Распространенные осложнения включают раннюю недостаточность аллотрансплантата, острое отторжение трансплантата, коронарную васкулопатию аллотрансплантата, почечную недостаточность, инфекции и рак. Причины вторичной дисфункции трансплантата необходимо учитывать после первой недели трансплантации. На сегодняшний день, гистологическая стратификация острого отторжения при помощи эндомиокардиальной биопсии с гистопатологией является стандартным методом диагностики острого отторжения, оценки его тяжести и ответа на терапию. К сожалению, этот метод инвазивный и имеет некоторые ограничения. В дополнение к этому острое отторжение имеет два фенотипа: острое клеточное отторжение и антитело-опосредованное отторжение, что затрудняет постановку гистопатологического диагноза. Вторичные негенетические методы мониторинга сердечного отторжения могут включать эхокардиографию, МРТ сердца, тропонин и другие методы. Надежный неинвазивный маркер для выявления острого отторжения до развития дисфункции трансплантата, возможно, приведет к лучшим результатам для тех пациентов, у которых есть вероятность развития отторжения аллотрансплантата. В нашем обзоре мы собрали последние данные о генетических неинвазивных биомаркерах, включая внеклеточную ДНК донорского происхождения, метилирование ДНК, профилирование экспрессии генов РНК (матричная РНК) и микро-РНК. Анализ метилирования внеклеточной ДНК может помочь различить различные типы острого отторжения. Метод микро-РНК может сыграть важную роль в будущем как цель разработки иммунодепрессантов. В основе анализа внеклеточной ДНК донорского происхождения лежит обнаружение однонуклеотидных полиморфизмов, отличающих ДНК донора от ДНК реципиента. Фракция внеклеточной ДНК донора быстро снижается после трансплантации и увеличивается только в случае острого отторжения или повреждения миокарда. Таким образом, генетические неинвазивные методы...

5 November 2025 in BMC Nephrology
Verified
Journal Article
Open access
PDF file
MBMirgul Bayanova
Mirgul Bayanova
ABAidos Bolatov
Aidos Bolatov
DMDias Malik
Dias Malik
MSMalika Sapargaliyeva
Malika Sapargaliyeva
AAAizhan Abdikadirova
Aizhan Abdikadirova
YPYuriy Pya
Yuriy Pya
Kidney transplantation is the preferred treatment for end-stage renal disease (ESRD), yet challenges persist in long-term graft survival and post-transplant complications. Genomic profiling, especially whole-exome sequencing (WES), offers new opportunities to personalize donor-recipient matching and predict transplant outcomes. This study aimed to explore the genetic landscape of both transplant recipients and donors using WES. This prospective cohort study included 64 kidney transplant recipients (51 adults, 13 pediatric) and 61 donors in Kazakhstan. WES was performed to identify monogenic causes of ESRD, evaluate rejection-associated immune polymorphisms (31 SNPs), and screen for post-transplant risk using a 355-gene Transplant Morbidity Panel. Variants were classified following ACMG/AMP guidelines, and allele frequencies were compared to global reference datasets. Among recipients, pathogenic/likely pathogenic variants were found in 15.4% of pediatric and 9.1% of adult cases, with additional variants of uncertain significance detected in 23.1% and 23.6%, respectively. WES identified monogenic nephropathies including Alport syndrome, cystinuria, and polycystic kidney disease. In donors, 13.1% carried variants associated with latent renal or systemic conditions despite no clinical manifestation at donation. The APOE p.Cys130Arg variant, linked to lipid dysregulation, was observed more frequently in recipients (allele frequency 0.17) than donors (0.09), though not statistically significant. Among the 31 SNPs evaluated, significant associations with acute rejection were observed for IL1B rs1143634 and TP53 rs1625895 under dominant models. IL1B carriers showed increased rejection risk (OR = 4.62, p = 0.039), whereas TP53 carriers appeared protected (OR = 0.058, p = 0.027). Given the limited number of rejection cases, these findings should be considered exploratory and require validation in larger cohorts. Additionally, 44.3% of recipients carried at least one pathogenic or likely pathogenic variant in the Transplant Morbidity Panel, particularly in genes related to malignancy, cardiomyopathy, and monogenic diabetes. This study provides one of the first applications of WES in a Central Asian kidney transplant population. Findings highlight the prevalence of monogenic and comorbid risk variants in both recipients and donors and support the use of genomic screening for improving pre- and post-transplant care. The identification of immune-related SNPs and extra-renal findings further underscores the utility of WES for personalized transplant management. Integration of genomics into transplant workflows may help address the ongoing gap between clinical need and transplant outcomes, particularly in low-resource settings.